Welcome to our dedicated page for Medifast SEC filings (Ticker: MED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medifast, Inc. (NYSE: MED) SEC filings page provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into how Medifast reports its financial condition, governance decisions, compensation plans, and key strategic developments related to its health and wellness and metabolic health business.
Among the most important filings for MED are annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain audited or reviewed financial statements, management’s discussion and analysis, and descriptions of risk factors relevant to Medifast’s coach-guided lifestyle system and metabolic health focus. Investors use these reports to understand revenue trends, margins, balance sheet strength, and the role of the OPTAVIA coach network in the company’s operations.
Medifast also files current reports on Form 8-K to disclose material events. Recent 8-K filings have addressed topics such as executive leadership transitions, changes in key officer roles, amendments to the company’s share incentive plan, and the release of quarterly earnings. These filings provide timely detail on matters like CEO succession planning, executive compensation arrangements, and shareholder votes on equity plans.
On this page, users can also review filings related to equity compensation and corporate governance, including documents that describe the Amended and Restated 2012 Share Incentive Plan and shareholder approval of additional share authorizations. Together, these materials help clarify how Medifast aligns incentives for executives, directors, and other participants in its equity programs.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods, and surface notable items such as leadership changes or plan amendments. Real-time updates from EDGAR, combined with easy access to forms like 10-K, 10-Q, and 8-K, allow investors and researchers to follow Medifast’s regulatory disclosures and governance developments efficiently.
Medifast Director Xian Ming received two grants of Restricted Stock Units (RSUs) on June 25, 2025:
- 11,167.65 cash-settled RSUs as part of director compensation, vesting fully on June 25, 2026
- 6,013.35 additional RSUs valued at $13.39 per share (based on 20-day moving average), elected in lieu of cash compensation
Both RSU grants will be payable in cash upon Ming's termination of service as director. Following these transactions, Ming beneficially owns 26,129.568 RSUs from the first grant and 32,142.918 RSUs from the second grant. The RSUs were granted under Medifast's Director's Deferred Compensation Plan and the Amended and Restated 2012 Share Incentive Plan.
Medifast Director Scott Schlackman received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and represent the right to receive an equivalent number of common shares.
Key details of the transaction:
- The RSUs will fully vest on June 25, 2026
- Shares are granted under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Schlackman owns 25,548.707 shares directly
- The grant is part of annual director compensation
The Form 4 was filed through an attorney-in-fact, Jason L. Groves, on June 26, 2025, within the required reporting timeline for insider transactions.
Director Andrea B Thomas of Medifast received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the Director's Deferred Compensation Plan. The RSUs were granted under the company's Amended and Restated 2012 Share Incentive Plan.
Key details of the transaction:
- RSUs were granted at $0 cost to the director
- Each unit represents one share of Medifast common stock
- Full vesting scheduled for June 25, 2026
- Following the transaction, Thomas owns 24,017.123 shares directly
This grant represents standard director compensation rather than an open market transaction. The filing was submitted by attorney-in-fact Jason L. Groves on June 26, 2025, within the required reporting timeframe.
Director Michael A. Hoer of Medifast received a significant equity grant of 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.
Key details of the transaction:
- Each RSU represents the right to receive one share of Medifast common stock
- The grant was made under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Hoer owns 26,139.473 shares directly
- The RSUs were granted in connection with annual director compensation
This Form 4 filing, signed by attorney-in-fact Jason L. Groves, indicates continued alignment of director interests with shareholders through equity-based compensation.
Medifast director Elizabeth A. Geary received 11,168 restricted stock units (RSUs) on June 25, 2025 as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.
Key details:
- Each RSU represents the right to receive one share of Medifast common stock
- The grant was made under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Geary directly owns 19,545 shares
- The RSUs were granted in connection with annual director compensation
This Form 4 filing indicates standard director equity compensation practices at Medifast, with a one-year vesting period for director RSU grants.
Medifast Director Jeffrey J. Brown reported significant stock acquisitions on June 25, 2025, through multiple transactions:
- Received 11,167.542 restricted stock units under the Director's Deferred Compensation Plan, which will fully vest on June 25, 2026
- Acquired 9,449.458 shares of common stock at $13.39 per share in lieu of cash compensation for director services
Following these transactions, Brown's total beneficial ownership includes:
- 38,577.647 shares held directly
- 4,232.967 shares held indirectly through the Jeffrey Brown Living Trust
The stock price was calculated using the 20-day moving average as of June 6, 2025. This Form 4 filing demonstrates significant insider accumulation of shares through compensation arrangements, suggesting continued alignment with shareholder interests.
Medifast, Inc. (NYSE: MED) filed an 8-K reporting the results of its 2025 Annual Meeting held on June 18, 2025.
Equity plan expansion: Shareholders approved an amendment to the Amended and Restated 2012 Share Incentive Plan, authorizing an additional 550,000 common shares for future equity awards. The plan became effective immediately and its full text is attached as Exhibit 10.1.
Board elections: All seven incumbent directors were re-elected. Support ranged from 90.3 % (Andrea B. Thomas) to 97.2 % (Jeffrey J. Brown) of votes cast, with 2.09 million broker non-votes recorded for each nominee.
Auditor ratification: RSM US LLP was ratified as independent auditor for FY 2025 with 99.2 % of votes in favor (8,225,570 for / 39,619 against).
Say-on-pay advisory vote: Compensation for named executive officers passed but with a modest margin—3,585,469 for vs. 2,477,849 against (59.1 % support, excluding abstentions).
Plan approval vote: The amended share incentive plan itself received 5,518,075 for vs. 664,416 against (88.2 % support, excluding abstentions).
No other material transactions, earnings data, or financial statements were disclosed.